Skip to main content
CELC logo

CELC · Celcuity Inc. · Documents

Track CELC — free
$56.48 +0.88 (+1.58%) Play latest call Q3 2026 earnings call transcript
Market Cap
$2.73B
Shares
49.13M
Volume · Nov 19 86.28K Avg daily vol (3M) 1.23M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $177.04M 10-K filed Mar 26, 2026 Quarterly report FY2026 Q3 Net loss $73.34M 10-Q filed Nov 5, 2026 Latest results REVTORPYK launches as net loss reaches $73.3 million 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
ReftraPIC launch advances as losses deepen

Celcuity Inc. launched ReftraPIC on September 30th; 78% of its top 36 accounts ordered, and 91% of U.S. commercial and Medicare lives are covered. No third-quarter product revenue was recognized; cash, cash equivalents, and short-term investments reached $642.7 million.

5 source passages
Earlier today, Cellcuity, Inc. released financial results where the quarter ended September 30, 2026. Since ReftraPIC became commercially available on September 30th, 78% of the top 36 strategic accounts have ordered ReftraPIC. 91% of U.S. commercial and Medicare lives are in health care plans that cover ReftorPIC. Because no product was received at the treatment location, Until after September 30th, 2026, we did not recognize any product revenue during the third quarter of 2026. Cash, cash equivalents, and short-term investments were $642.7 million at the end of the third quarter, compared to $441.5 million as of December 31, 2025. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
REVTORPYK launches after FDA approval

Celcuity launched REVTORPYK after FDA approval for adults with HR+/HER2- ABC without a PIK3CA mutation, but recognized no product revenue through September 30, 2026; its nine-month net loss was $205.0 million.

Net loss $73.34M Diluted EPS -$1.33
Read from the MD&A section
3 source passages
On July 14, 2026, the FDA approved our NDA for REVTORPYK in HR+/HER2- ABC, for use in adult patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Shipments of REVTORPYK commenced on September 30, 2026. We recognize revenue when control of REVTORPYK transfers to the healthcare providers or pharmacies, which generally occurs upon delivery of REVTORPYK based on contractual shipping terms. Because no product was received by the healthcare providers or pharmacies until after September 30, 2026, we did not recognize any product revenue during the three and nine months ended September 30, 2026. During the nine months ended September 30, 2026 and 2025, we reported a net loss of $205.0 million and $126.1 million, respectively. Open the document at this passage
Nov 5
Current report 8-K
REVTORPYK launches as net loss reaches $73.3 million

Celcuity Inc. launched REVTORPYK on September 30, 2026, with 91% of U.S. commercial and Medicare lives covered; third-quarter net loss was $73.3 million, and no product revenue was recognized.

Financial results
4 source passages
Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the third quarter ended September 30, 2026, and other recent business developments. 91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK Net loss for the third quarter of 2026 was $73.3 million, or $1.33 per share, compared to a net loss of $43.8 million, or $0.92 per share, for the prior year period. Because no product was received by the healthcare providers or pharmacies until after September 30, 2026, we did not recognize any product revenue during the third quarter ended September 30, 2026. Open the document at this passage
Oct 2
Current report 8-K Events of Oct 1
Director or officer change, or executive pay, Regulation FD disclosure

Celcuity Inc. appointed David W. Gryska to its expanded nine-member Board effective October 1, 2026, and to its Audit and Compensation Committees, with a $70,000 annual cash retainer, $100,000 annual equity award, and 893 restricted stock units.

Sep 30
Current report 8-K
Regulation FD disclosure, Other events

Celcuity launched REVTORPYK (gedatolisib) in the United States for eligible adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation detected after at least one line of metastatic endocrine therapy.

Mar 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $177.04M Diluted EPS -$3.79
2025
Showing 1–50 of 173 documents
Key facts CIK 1603454 CUSIP 15102K100 13F (30d) 273 filings 259 filers Visit website Investor relations